Glaxosmithkline Phar
Ticker >

Glaxosmithkline Phar share price

Glaxosmithkline Pharmaceuticals Ltd.

NSE: GLAXO BSE: 500660 SECTOR: Pharmaceuticals & Drugs  88k   373   47

2118.00
+52.40 (2.54%)
NSE: Today, 12:34 PM

Price Summary

Today's High

₹ 2136

Today's Low

₹ 2053

52 Week High

₹ 2524

52 Week Low

₹ 1227

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 35880.2 Cr.

Enterprise Value

₹ 34729.47 Cr.

No. of Shares

16.94 Cr.

P/E

68.59

P/B

22.52

Face Value

₹ 10

Div. Yield

1.55 %

Book Value (TTM)

₹  94.04

CASH

₹ 1150.73 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

75 %

EPS (TTM)

₹  30.88

Sales Growth

-0.04%

ROE

27.29 %

ROCE

37.66%

Profit Growth

60.58 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Glaxosmithkline Pharmaceuticals Ltd.

Piriton Betnovate Augmentin Ceftum Calpol Phexin Betnesol Eltroxin Zinetac Neosporin Cetzine Havrix Varilrix Rotarix Hiberix Cervarix Crocin Eno IODEX Horlicks OSTOCALCIUM Otrivin ActiGrow Choco

Index Presence

The company is present in 19 Indices.

NMID150Q50

NIFTY Midcap150 Quality 50
21083.400390625
  231.650390625 (1.11093980421308%)

NIFTY500

Nifty 500
20920.30078125
  52.4007812499985 (0.251107113077964%)

NIFTYMIDCAP150

Nifty Midcap 150
18810.349609375
  167.099609375 (0.896300856208021%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
17806.150390625
  155.500390624999 (0.880989598824966%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
14551.650390625
  66.900390625 (0.461867761783941%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
14457.2998046875
  67.4998046875007 (0.469080909307285%)

NIFTYTOTALMCAP

Nifty Total Market index
11763.25
  29.5499999999993 (0.251838720949049%)

MIDCAP

S&P Bse Mid Cap
41598.59
  641.889999999999 (1.5672405247493%)

BSE HC

S&P Bse Healthcare
35509.74
  567.68 (1.62463231990329%)

BSE500

S&P Bse 500
33014.93
  298.66 (0.912879127113198%)

MID150

S&P Bse 150 MidCap
14100.15
  202.629999999999 (1.45802992188533%)

MSL400

S&P Bse 400 MidSmallCap
10815.64
  159.349999999999 (1.49536095582983%)

BSE200

S&P Bse 200
10320.3
  85.9799999999996 (0.840114438477579%)

LMI250

S&P Bse 250 LargeMidCap
9785.11
  82.2399999999998 (0.847584271457813%)

ALLCAP

S&P Bse Allcap
9638.71
  87.4199999999983 (0.915269036957289%)

SPBSMOIP

S&P Bse Momentum
2029.4
  45.1200000000001 (2.2738726389421%)

SPBSQIP

S&P Bse Quality
1728.63
  25.5500000000002 (1.50022312516149%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
9712.77
  64.1499999999996 (0.664861918077397%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
11797.89
  72.8899999999994 (0.621663113006399%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-0.04%
3 Year-0.09%
5 Year2.29%

Profit Growth

1 Year-64.05%
3 Year76.76%
5 Year11.54%

ROE%

1 Year27.29%
3 Year20.84%
5 Year17.64%

ROCE %

1 Year37.66%
3 Year34.06%
5 Year30.03%

Debt/Equity

0

Price to Cash Flow

73.53

Interest Cover Ratio

460.682460790811

CFO/PAT (5 Yr. Avg.)

1.55526597044247

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 75 0
Dec 2023 75 0
Sep 2023 75 0
Jun 2023 75 0
Mar 2023 75 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 76.4607844896831% for the Past 3 years.
  • Company has been maintaining healthy ROE of 20.8362530975162% over the past 3 years.
  • Company has been maintaining healthy ROCE of 34.0591831884345% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 460.682460790811.
  • The Company has been maintaining an effective average operating margins of 20.4293109605686% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of -72.5638486521992 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.55526597044247.
  • The company has a high promoter holding of 75%.

 Limitations

  • The company has shown a poor revenue growth of -0.086250530503218% for the Past 3 years.
  • The company is trading at a high EV/EBITDA of 36.2245.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 799.11 782.16 738.02 953.38 804.98
Total Expenditure 571.31 615.4 596.77 666.8 587.47
Operating Profit 227.8 166.76 141.25 286.58 217.51
Other Income 23.6 27.97 36.8 28.47 28.34
Interest 0.09 0.65 0.28 0.43 0.32
Depreciation 16.41 17.18 16.36 18.11 17.11
Exceptional Items -11.37 10.4 17.3 0 -163.31
Profit Before Tax 223.53 187.3 178.71 296.51 65.11
Tax 59.5 55.82 48.13 80.97 19.62
Profit After Tax 164.03 131.48 130.58 215.54 45.49
Adjusted EPS (Rs) 9.68 7.76 7.71 12.72 2.69

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 3128.53 3224.68 2920.48 3217.51 3216.34
Total Expenditure 2522.05 2566.23 2322.7 2461.68 2416.92
Operating Profit 606.48 658.45 597.77 755.83 799.43
Other Income 101.48 77.56 110.19 76.22 101.51
Interest 0.55 6.34 3.53 1.99 1.81
Depreciation 48.59 82.68 78.6 68.19 65.77
Exceptional Items 4.89 -324.49 -172.6 11.58 -0.97
Profit Before Tax 663.71 322.5 453.23 773.44 832.39
Tax 238.35 212.45 166.54 396.87 227.69
Net Profit 425.36 110.05 357.57 1690.53 607.75
Adjusted EPS (Rs.) 25.11 6.5 16.92 22.23 35.7

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 169.41 169.41 169.41 169.41 169.41
Total Reserves 1973.01 1670.63 1327.71 2508.21 1583.59
Borrowings 0.18 0.02 0 0 0
Other N/C liabilities 2834.88 180.54 178.87 157.84 124.49
Current liabilities 2800.62 1002.07 1319.42 1674.35 1317.03
Total Liabilities 7778.1 3022.68 2995.41 4509.81 3194.52
Assets
Net Block 429.99 756.59 385.56 329.44 328.9
Capital WIP 1002.64 120.12 13.21 30.5 20.31
Intangible WIP 0 0 0 0 0
Investments 24.55 24.49 24.49 24.49 24.49
Loans & Advances 2970.52 356.05 392.45 448.04 347.22
Other N/C Assets 12.78 8.75 188.48 6.74 6.88
Current Assets 3337.6 1756.67 1991.21 3670.6 2466.72
Total Assets 7778.1 3022.68 2995.41 4509.81 3194.52
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 658.82 646.99 722.33 2470.04 837.49
Adjustment -30.52 14.2 -25.25 -1636.93 -40.86
Changes in Assets & Liabilities -7.58 43.59 63.03 134.89 -39.02
Tax Paid -194.15 -179.55 -146.91 -112.15 -260.57
Operating Cash Flow 411.18 490.97 594.87 819.79 487.94
Investing Cash Flow -154.44 -63.1 407.57 -419.66 805.19
Financing Cash Flow -358.36 -427.62 -695.56 -524.24 -1544.18
Net Cash Flow -101.62 0.25 306.87 -124.11 -251.05

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 75.00 75.00 75.00 75.00 75.00
burroughs wellcome intern... 3.97 3.97 3.97 3.97 3.97
eskaylab limited 6.94 6.94 6.94 6.94 6.94
glaxo group limited 35.99 35.99 35.99 35.99 35.99
glaxosmithkline pte limit... 28.10 28.10 28.10 28.10 28.10
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 25.00 25.00 25.00 25.00 25.00
aditya birla sun life tru... 1.70 1.30 1.22 1.14 1.01
investor education and pr... - 0.57 - 0.58 0.58
lici asm non par - - - - 1.94
icici prudential large & ... - - - 1.27 -
life insurance corporatio... 3.66 3.36 - 2.28 -
nippon life india trustee... - - - 1.03 -
general insurance corpora... 1.45 1.45 1.25 - -
icici prudential mnc fund... - - 2.43 - -
investor education and pr... 0.57 - 0.58 - -
lici money plus growth fu... - - 2.93 - -
icici prudential midcap 1... - 2.17 - - -
icici prudential nifty ph... 1.51 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

GlaxoSmithKline Pharmaceuticals informs about issue of duplicate share certificates24 Apr 2024, 11:41AM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates16 Apr 2024, 12:03PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificate 5 Apr 2024, 12:54PM Glaxosmithkline Pharmaceuticals informs about details of loss of certificate 4 Apr 2024, 12:29PM GlaxoSmithKline Pharmaceuticals informs about certificate2 Apr 2024, 5:29PM Glaxosmithkline Pharmaceuticals informs about compliances-certificate2 Apr 2024, 4:49PM Glaxosmithkline Pharmaceuticals informs about details of loss of certificate 13 Mar 2024, 12:37PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates6 Mar 2024, 12:24PM Glaxosmithkline Pharmaceuticals informs about issue of duplicate share certificates27 Feb 2024, 3:07PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates23 Feb 2024, 12:25PM Glaxosmithkline Pharmaceuticals informs about analyst meet21 Feb 2024, 5:07PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates20 Feb 2024, 12:25PM Glaxosmithkline Pharmaceuticals informs about press release 12 Feb 2024, 5:23PM Glaxosmithkline Phar - Quaterly Results12 Feb 2024, 4:55PM Glaxosmithkline Phar - Quaterly Results12 Feb 2024, 4:55PM Glaxosmithkline Phar - Quaterly Results12 Feb 2024, 4:55PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates2 Feb 2024, 10:54AM Glaxosmithkline Pharmaceuticals informs about disclosure1 Feb 2024, 5:26PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificate 25 Jan 2024, 12:08PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates4 Jan 2024, 12:08PM Glaxosmithkline Pharmaceuticals informs about details of loss of certificate 15 Dec 2023, 12:25PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates14 Dec 2023, 12:29PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates13 Dec 2023, 5:11PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates 8 Dec 2023, 12:42PM GlaxoSmithKline Pharmaceuticals establishes Omnichannel Team to expand reach7 Dec 2023, 5:19PM Glaxosmithkline Pharmaceuticals informs about resignation of senior managerial personnel6 Dec 2023, 4:13PM Glaxosmithkline Pharmaceuticals informs about disclosure6 Dec 2023, 2:05PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates16 Nov 2023, 11:54AM Glaxosmithkline Phar - Quaterly Results9 Nov 2023, 4:35PM Glaxosmithkline Phar - Quaterly Results9 Nov 2023, 4:35PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates7 Nov 2023, 2:22PM Glaxosmithkline Pharmaceuticals informs about disclosure28 Oct 2023, 11:47AM Glaxosmithkline Pharmaceuticals informs about details of loss of certificate17 Oct 2023, 4:32PM GlaxoSmithKline Pharmaceuticals informs about ODR portal9 Oct 2023, 4:57PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificates9 Oct 2023, 12:49PM Glaxosmithkline Pharmaceuticals informs about details of loss of certificate5 Oct 2023, 12:43PM Glaxosmithkline Pharmaceuticals informs about issue of duplicate share certificates29 Sep 2023, 3:13PM Glaxosmithkline Phar - Quaterly Results26 Jul 2023, 1:45PM Glaxosmithkline Phar - Quaterly Results26 Jul 2023, 1:45PM Glaxosmithkline Phar - Quaterly Results26 Jul 2023, 1:45PM GlaxoSmithKline Pharmaceutical informs about newspaper advertisement 22 Jun 2023, 5:06PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificate22 Jun 2023, 4:42PM Glaxosmithkline Pharmaceuticals informs about details of loss of certificate2 Jun 2023, 12:32PM Glaxosmithkline Phar - Quaterly Results17 May 2023, 4:51PM Glaxosmithkline Phar - Quaterly Results17 May 2023, 4:51PM Glaxosmithkline Phar - Quaterly Results17 May 2023, 4:51PM GlaxoSmithKline Pharmaceuticals informs about issuance of duplicate share certificate28 Apr 2023, 4:36PM Glaxosmithkline Pharmaceuticals informs about details of loss of certificate23 Mar 2023, 4:02PM Glaxosmithkline Pharmaceuticals informs about issue of duplicate share certificate23 Mar 2023, 3:06PM GlaxoSmithKline Pharmaceuticals informs about institutional investors meeting13 Mar 2023, 5:15PM

Glaxosmithkline Phar Stock Price Analysis and Quick Research Report. Is Glaxosmithkline Phar an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Glaxosmithkline Phar and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Glaxosmithkline Phar cash from the operating activity was Rs 487.9359 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Glaxosmithkline Phar has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Glaxosmithkline Phar , the EPS growth was 60.5802278084682 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Glaxosmithkline Phar has OPM of 24.8551289641523 % which is a good sign for profitability.
     
  • ROE: Glaxosmithkline Phar have a healthy ROE of 27.2864080606207 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Glaxosmithkline Phar is Rs 2060.8. One can use valuation calculators of ticker to know if Glaxosmithkline Phar share price is undervalued or overvalued.
Last Updated on:
Brief about Glaxosmithkline Phar

Glaxosmithkline Pharmaceuticals Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Glaxosmithkline Pharmaceuticals Ltd. is a leading pharmaceutical company in India, providing a wide range of healthcare products to its customers.  We will provide a comprehensive analysis of Glaxosmithkline Pharmaceuticals Ltd.'s stock performance and key financial indicators for long-term stock investors looking for stock analysis.

Glaxosmithkline Pharmaceuticals Ltd. Share Price

Glaxosmithkline Pharmaceuticals Ltd.'s share price has been consistently increasing over the years due to the company's strong financial performance and growth prospects. The company has a stable business model and a diverse range of clients, which provides investors with a sense of security and stability. Investors can use Ticker pre-built screening tools to track Glaxosmithkline Pharmaceuticals Ltd.'s share price and compare it with other companies in the industry.

Glaxosmithkline Pharmaceuticals Ltd. Balance Sheet

Glaxosmithkline Pharmaceuticals Ltd.'s balance sheet is a reflection of the company's financial health and stability. The company has a strong balance sheet with a healthy debt-to-equity ratio and a high current ratio. Ticker premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools provide investors with a comprehensive understanding of the company's financial position and help them make informed investment decisions.

Glaxosmithkline Pharmaceuticals Ltd. Annual Report

Glaxosmithkline Pharmaceuticals Ltd.'s annual reports provide detailed information about the company's operations, financial performance, and future prospects. Investors can download the annual reports from Ticker and analyze the company's performance over the years. The annual report also includes information about the company's management team, corporate governance practices, and sustainability initiatives.

Glaxosmithkline Pharmaceuticals Ltd. Dividend

Glaxosmithkline Pharmaceuticals Ltd. has a consistent track record of paying dividends to its shareholders. The company has a dividend payout ratio of over 30%, which indicates that it is committed to sharing its profits with its shareholders. Investors can track Glaxosmithkline Pharmaceuticals Ltd.'s dividend history using Ticker pre-built screening tools and compare it with other companies in the industry.

Glaxosmithkline Pharmaceuticals Ltd. Quarterly Result

Glaxosmithkline Pharmaceuticals Ltd.'s quarterly results provide an insight into the company's performance over a shorter period. The company's revenue and profits can be affected by various factors such as changes in government policies, fluctuations in commodity prices, and global economic conditions. Ticker premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools provide investors with a comprehensive understanding of the company's financial position and help them make informed investment decisions.

Glaxosmithkline Pharmaceuticals Ltd. Stock Price

Glaxosmithkline Pharmaceuticals Ltd.'s stock price is influenced by various factors such as the company's financial performance, market conditions, and investor sentiment. Investors can track Glaxosmithkline Pharmaceuticals Ltd.'s stock price using our pre-built screening tools and compare it with other companies in the industry. 

Glaxosmithkline Pharmaceuticals Ltd. Price Chart

Glaxosmithkline Pharmaceuticals Ltd.'s price chart provides a visual representation of the company's stock performance over a period of time. Investors can use our pre-built screening tools to analyze Glaxosmithkline Pharmaceuticals Ltd.'s price chart and compare it with other companies in the industry. 

Glaxosmithkline Pharmaceuticals Ltd. News

Glaxosmithkline Pharmaceuticals Ltd.'s news section provides investors with the latest updates about the company's operations, financial performance, and future prospects. Investors can stay informed about the company's developments by regularly checking the news section on Ticker.

Glaxosmithkline Pharmaceuticals Ltd. Concall Transcripts

Glaxosmithkline Pharmaceuticals Ltd.'s concall transcripts provide investors with an opportunity to listen to the management team's views on the company's performance and future prospects. Investors can download the concall transcripts from Ticker and gain valuable insights into the company's operations.

Glaxosmithkline Pharmaceuticals Ltd. Investor Presentations

Glaxosmithkline Pharmaceuticals Ltd.'s investor presentations provide a comprehensive overview of the company's operations, financial performance, and future prospects. Investors can download the investor presentations from Ticker and gain a deeper understanding of the company's business model and growth prospects.

Glaxosmithkline Pharmaceuticals Ltd. Promoters

Glaxosmithkline Pharmaceuticals Ltd.'s promoters include some of the leading business conglomerates in India. The company has a strong backing from its promoters, which provides investors with a sense of security and stability.

Glaxosmithkline Pharmaceuticals Ltd. Shareholders

Glaxosmithkline Pharmaceuticals Ltd.'s shareholders include retail investors, institutional investors, and the company's promoters. The company has a diverse shareholder base, which indicates that it is a popular investment choice among investors.

Read More
X